Coronary/Structural Heart

Cytokinetics Presents Additional Data from SEQUOIA-HCM at the HCMS Scientific Sessions

Coronary/Structural Heart by Comments are Disabled

SOUTH SAN FRANCISCO, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data from SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), were presented at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions by Anjali T. Owens, M.D., Medical Director of the Center for Inherited Cardiac Disease and Assistant Professor of Medicine at the University of Pennsylvania.

Continue Reading →

United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2024 Annual Meeting

Coronary/Structural Heart by 0 comments

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that five presentations and one poster across its commercial and development portfolio will be presented at the CHEST 2024 Annual Meeting hosted […]

Continue Reading →

Annals of Family Medicine: Systematic Review Highlights Promise of High-Sensitivity Troponin in Diagnosing Acute Coronary Syndrome in Primary Care Settings

Coronary/Structural Heart by Comments are Disabled

PROVIDENCE, R.I., Sept. 24, 2024 /PRNewswire/ — Findings from a new systematic review, titled “Chest Pain in Primary Care: A Systematic Review of Risk Stratification Tools to Rule Out Acute Coronary Syndrome,” published in Annals of Family Medicine, suggest that high-sensitivity troponin…

Continue Reading →

Rivus Pharmaceuticals to Present New Data from Phase 2a HuMAIN Trial of HU6 for the Treatment of Obesity-Related Heart Failure with Preserved Ejection Fraction at Heart Failure Society of America Annual Scientific Meeting 2024

Coronary/Structural Heart by Comments are Disabled

– New data from the HuMAIN study, which met the primary endpoint of weight loss and several efficacy and pharmacodynamic secondary endpoints, will be presented in a Late Breaking Clinical Research Session – – HU6, a novel oral, once-daily Controlled Metabolic Accelerator, is a new class…

Continue Reading →

Professor Luo Min Invited to Attend World Congress on Cardiology and Heart Disease in London this October to Share New Findings on His Innovative Heart Disease Treatments

Coronary/Structural Heart by Comments are Disabled

BEIJING, Sept. 23, 2024 /PRNewswire/ — Professor Luo Min, from Beijing Yuhe Integrated Traditional Chinese and Western Medicine Rehabilitation Hospital, has been invited to attend the 36th World Congress on Cardiology and Heart Disease on October 17-18, 2024 in London to introduce his…

Continue Reading →

Translumina Therapeutics, India’s largest domestic player in the coronary stents market, announces the initiation of direct operations in the UAE

Coronary/Structural Heart by Comments are Disabled

NEW DELHI, Sept. 21, 2024 /PRNewswire/ — Translumina was incorporated in 2011 as a sales & marketing company specialising in coronary intervention devices. Since its inception, the company has successfully established their own manufacturing capabilities and developed in-house product…

Continue Reading →

Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time

Coronary/Structural Heart by 0 comments

BOULDER, Colo.–(BUSINESS WIRE)–Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that members of the management team will hold a live webcast to discuss top-line data of EDG-7500 from the Phase 1 trial in healthy subjects […]

Continue Reading →

Edwards Launches SAPIEN 3 With Alterra Prestent in Europe for Transcatheter Pulmonic Valve Implantation

Coronary/Structural Heart by 0 comments

September 16, 2024 07:01 PM Eastern Daylight Time NYON, Switzerland–(BUSINESS WIRE)–Edwards Lifesciences today announced the launch in Europe of the SAPIEN 3 transcatheter pulmonary valve implantation (TPVI) system with Alterra adaptive prestent, expanding minimally invasive treatment options to a broader […]

Continue Reading →
1 2 3 4 5 … 371